

Age-related sensory neuropathy in patients with Spinal Muscular Atrophy type 1

Pro, Stefano; Tozzi, Alberto Eugenio; D'Amico, Adele; Catteruccia, Michela; Cherchi, Claudio; De Luca, Massimiliano; Nicita, Francesco; Diodato, Daria; Cutrera, Renato; Bertini, Enrico; Valeriani, Massimiliano

Published in:
Muscle & Nerve

DOI (link to publication from Publisher):
[10.1002/mus.27389](https://doi.org/10.1002/mus.27389)

Publication date:
2021

Document Version
Accepted author manuscript, peer reviewed version

[Link to publication from Aalborg University](#)

Citation for published version (APA):

Pro, S., Tozzi, A. E., D'Amico, A., Catteruccia, M., Cherchi, C., De Luca, M., Nicita, F., Diodato, D., Cutrera, R., Bertini, E., & Valeriani, M. (2021). Age-related sensory neuropathy in patients with Spinal Muscular Atrophy type 1. *Muscle & Nerve*, 64(5), 599-603. <https://doi.org/10.1002/mus.27389>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

Take down policy

If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.



FOR PEOPLE LIVING WITH POMPE DISEASE, MOBILITY CAN'T TAKE A DAY OFF

Not a real patient.

People living with late-onset Pompe disease (LOPD) face obstacles that may challenge their well-being and livelihood. A 2011 Dutch survey of LOPD patients showed^{1,2}:

40% (n=32/80) stopped working due to their disease

85% required support from more than 1 caregiver to help with household tasks such as cleaning and grocery shopping

As Pompe disease progresses, it can lead to irreversible loss of mobility, respiratory function, and ability to perform daily activities, as well as premature death.^{3,4} In a 2007 international study⁵:

42% of patients with LOPD depended on a wheelchair

46% required respiratory support

Regular evaluation is recommended in patients with Pompe disease to assess for disease progression and to understand the impact on daily activities and lifestyles.³

Explore Pompe disease and its impact on patients at
MORETOPOMPE.COM

*Mean disease duration of patients studied was 11 years.

References: 1. Schoser B, Hahn A, James E, Gupta D, Gitlin M, Prasad S. A systematic review of the health economics of Pompe disease. *Pharmacoecon Open*. 2019;3(4):479-493. 2. Kanter TA, Hagemans ML, van der Beek NA, Rutten FF, van der Ploeg AT, Hakkaart L. Burden of illness of Pompe disease in patients only receiving supportive care. *J Inher Metab Dis*. 2011;34(5):1045-1052. 3. Kishnani PS, Steiner RD, Bali D, et al. Pompe disease diagnosis and management guideline. *Genet Med*. 2006;8(5):267-288. 4. Yuan M, Andrinopoulou ER, Kruijshaar ME, et al. Positive association between physical outcomes and patient-reported outcomes in late-onset Pompe disease: a cross sectional study. *Orphanet J Rare Dis*. 2020;15(1):232. 5. Hagemans ML, Laforet P, Hop WJ, et al. Impact of late-onset Pompe disease on participation in daily life activities: evaluation of the Rotterdam Handicap Scale. *Neuromuscul Disord*. 2007;17(7):537-543.

© 2020 Amicus Therapeutics, Inc. All rights reserved. NP-US-00011120

Amicus
Therapeutics

Title Page

Age-related sensory neuropathy in patients with Spinal Muscular Atrophy type 1

Stefano Pro MD, PhD¹, Alberto Eugenio Tozzi MD², Adele D'Amico MD, PhD³, Michela Catteruccia MD³, Claudio Cherchi MD⁴, Massimiliano De Luca¹, Francesco Nicita MD, PhD³, Daria Diodato MD, PhD³, Renato Cutrera MD, PhD⁴, Enrico Bertini MD³, Massimiliano Valeriani MD, PhD^{5,6}

¹Neurophysiology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

²Predictive and Preventive Medicine Research Unit, Bambino Gesù Children Hospital IRCCS, Rome, Italy

³Unit of Neuromuscular and Neurodegenerative Diseases, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

⁴Bronchopneumology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

⁵Neurology Ward Unit, Bambino Gesù Hospital, Rome, Italy

⁶Center for Sensory-Motor Interaction, Aalborg University, Aalborg, Denmark

Acknowledgments: We are grateful to Dr. Claudia Ruscitto for her assistance and for her help in drafting the manuscript.

Number of words in abstract: 145

Number of words in manuscript: 1416

Correspondence to Stefano Pro; address: Piazza Sant'Onofrio 4 00165 Rome – Italy; e-mail: stefano.pro@opbg.net

Running title: sensory neuropathy in SMA type 1

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the [Version of Record](https://doi.org/10.1002/mus.27389). Please cite this article as doi: [10.1002/mus.27389](https://doi.org/10.1002/mus.27389)

This article is protected by copyright. All rights reserved.

Ethical Publication Statement: we confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Disclosure of Conflict of Interest: none of the authors has any conflict of interest to disclose.

Age-related sensory neuropathy in patients with Spinal Muscular Atrophy type 1

Abstract

Introduction: Spinal muscular atrophy type 1 (SMA 1) is a devastating motor neuron disorder that leads to progressive muscle weakness, respiratory failure and premature death. Although sensory electrophysiological changes have been anecdotally found in pediatric SMA 1 patients, the age of onset of sensory neuropathy remains unknown.

Methods: Sensory nerve conduction studies (SNCS) of the median and sural nerves were performed in 28 consecutive SMA 1 patients of different ages. Sensory nerve conduction velocities (SNCV) and sensory nerve action potential (SNAP) amplitudes recorded in these patients were compared with those obtained from 93 healthy subjects stratified by age.

Results: SNAP amplitudes decreased with increasing age in the sural and median nerves, without any significant difference between upper and lower limbs. *Discussion:* Our data suggest that sural and median nerve SNAP amplitudes are normal in younger patients, while an axonal neuropathy appears in older ones.

Key Words:

SMA 1

SNAP

Median Nerve

Sural Nerve

Sensory Neuropathy

INTRODUCTION

Spinal muscular atrophy (SMA) is a progressive neuromuscular disorder characterized by degeneration of spinal cord alpha motor neurons with progressive muscle atrophy and weakness¹.

Advances in the treatment of SMA, have resulted in longer life expectancy, new therapeutic and neurophysiological research, and a better clinical and neurophysiological understanding of this disease. Although SMA has been classified as a lower motor neuron disease, there are other neurological cells and other tissue types that are selectively vulnerable to reduced levels of SMN protein. This explains why SMA, especially in the more severe forms, may show multi-organ involvement²⁻⁴.

Experimental animal studies suggest that early dysfunction of sensory neurons and disruption of sensorimotor circuits could be involved in the pathophysiological mechanism of SMA 1⁵⁻¹². Axonal degeneration in sensory nerves of SMA 1 patients was demonstrated by both histological¹³⁻¹⁶ and electrophysiological studies¹⁷⁻²¹. However, it is still not clear whether sensory neuropathy in SMA 1 is an age and/or length-dependent process.

The aim of this study is to evaluate the sensory nerve conduction velocities (SNCVs) and sensory nerve action potential (SNAP) amplitudes of nerves of different lengths in patients with SMA 1 aged 0 to 16 years, and to compare the results with those from healthy subjects stratified by age.

METHODS

All patients enrolled in this prospective study had a homozygous deletion of exon 7.

IRB/local ethics committee approval was obtained, and the parents of all enrolled study subjects provided informed consent. At the time of our examination none of the recruited patients was included in an experimental treatment trial and no targeted genetic therapies

for SMA were available. Other possible etiologies of sensory neuropathy were excluded. A medication history was obtained from all study participants. All secondary neuropathies were ruled out through a nutritional evaluation with the support of specific laboratory studies that excluded any metabolic abnormalities. Glucose values were always normal and vitamin deficiencies were excluded in all subjects. Patients with feeding and swallowing dysfunction were supported with percutaneous gastrostomy tubes.

Sensory nerve conduction studies were performed in all our patients and in healthy subjects. Age groups were chosen to make the statistical analysis more homogeneous. Inclusion criteria for healthy subjects were no abnormal neurological signs or symptoms and normal laboratory tests.

Sensory nerve conduction studies

SNAPs were recorded from the right sural and median nerves. All procedures were carried out using pediatric surface recording electrodes and pediatric bipolar stimulating electrodes. Skin temperature was $\geq 34^{\circ}\text{C}$. For the median nerve, the SNAP was recorded by a ring electrode on the second phalanx of the third finger performing antidromic stimulation of the nerve at the wrist. Sural SNAP was recorded by two electrodes placed below the lateral malleolus, stimulating antidromically over the calf, immediately lateral to the midline. The active recording electrode and the reference electrode were placed 2 cm apart, with the first placed just behind the superior edge of the lateral malleolus. Each SNAP analyzed was obtained by the average of approximately 30 responses evoked by a supramaximal stimulation of the sensory nerve. SNCV was measured using the SNAP onset latency. SNAP amplitude was measured from baseline to negative peak.

Statistical analysis

SNAP amplitudes and SNCV values were described as median and interquartile range.

Patients with SMA 1 were compared with healthy subjects by age group. Nonparametric Mann-Whitney U-Test for independent samples was used for the comparisons. Statistical significance was set at $p < 0.05$.

RESULTS

Twenty-eight SMA 1 patients with 2 copies of the *SMN2* gene were enrolled (mean age 6.73 ± 4.3 yrs, 20 females and 8 males), consisting of 3 with SMA 1 subtype 1a, 16 with 1b, and 9 with 1c. No recordable SNAPs were obtained from the sural nerves in 2 patients (both age 12 years) and from both the median and sural nerves in 2 patients (ages 14 and 16 years). Healthy subjects had a mean age 7.03 ± 4.9 yrs (58 females and 35 males). See Table.1 for neurophysiological data.

While in the 2 lower age subgroups (6-24 months and 3-6 years) no statistically significant differences were found between SMA 1 patients and healthy controls, in the third group (7-16 years) the amplitude of the SNAP was significantly lower in SMA 1 patients than in healthy controls for both the median and sural nerves. In this subgroup, we also found a lower SNCV in the sural nerve in patients than in healthy controls (Figure.1).

At the time of the SNCS, 17 patients required invasive respiratory care with tracheostomy, 8 patients required nocturnal ventilation with bilevel positive airway pressure, and 3 patients required no respiratory support.

DISCUSSION

Our study reveals a connection between the development of an axonal sensory neuropathy and increasing of age in SMA 1 patients.

The data obtained from our study were compared with an external reference that reports the nerve conduction values in normal individuals (data not shown).²² This comparison suggests that nerve amplitude remains above minimum normal values until 6 years of age and declines in older children, while nerve velocity decreases beginning at 3 years of age.

Although there is some evidence of sensory involvement in SMA 1, published data are scarce and often highly variable. In a sural nerve conduction study in seven unrelated children with SMA 1 the data obtained appeared to be more consistent with an axonal neuropathy.¹⁶ Five out of seven patients showed also an abnormal sensory conduction velocity. Different degrees of axonal loss involving the sural nerves were observed which was particularly severe in four patients. Our results, showing an axonal sensory neuropathy in SMA 1 patients, also agree with what has been found in mouse models of this disease. Sensory neurons cultured from a mouse model of SMA showed defects in neurite outgrowth and growth cone morphology, together with a reduction of beta-actin protein and mRNA in growth cones.⁸ Moreover, in mouse models of SMA, sensory neurons were smaller than in control mice, consistent with a reduced overall size of the dorsal root ganglia (DRG).²³ SMA mice also showed a reduction of myelinated dorsal root axons⁹ and sensory fibers passing into the ventral horn.⁷ Structural defects of sensory neurons have been found to be associated with defects at the level of sensory-motor synapses.²⁴ Overall reduction of sensory synapses was mostly due to a reduction of vGlut1-positive synapses which primarily originate from proprioceptive neurons. This central feature of sensory-motor involvement appears to be a conserved feature of the disease, since it was observed in different SMA mouse models, including the commonly

used Taiwanese and delta7 models.^{9,23} All these data suggest that sensory-motor connectivity defects reported in SMA mice may correspond to the sensory-motor pathology observed in patients.

The small sample of older subjects included in this study represent a limitation of this paper. In addition, particularly in the group of patients with tracheostomy, is not clear whether the sensory nerve abnormalities are primarily due to the SMN protein deficiency or to a secondary neuropathy due to ICU complications. Further studies may clarify the trend of sensory neuropathy in SMA 1 patients during age development by studying the trends of SNAPs in the same patients over time.

A clinical trial of intrathecal AAV9 in patients with spinal muscular atrophy type 2 was recently placed on hold because of DRG toxicity in nonhuman primates.²⁵ The clinical significance of the DRG inflammation observed in this pre-clinical animal study was not clear and was not seen in prior animal studies with AVXS-101. DRG inflammation may be associated with sensory symptoms.²⁵

CONCLUSIONS

Our study shows that sural and median nerve SNAP amplitudes are normal in younger SMA 1 patients, while an axonal neuropathy appears later. Since sensory nerves in both upper and lower limbs are involved, our data do not statistically support a possible length-dependent process. However, the link between axonal damage and increasing age was supported by the absence of sural SNAPs in two older patients and of the median and sural SNAPs in two others. Monitoring SNAP amplitudes could therefore provide further information on the evolution of the disease.

The neurophysiological assessment of the peripheral somatosensory system should be included in the evaluation of patients with SMA 1. This could aid the development of new therapeutic strategies that will benefit and support all SMA patients.

List of acronyms or abbreviations:

SMA 1 (Spinal muscular atrophy type 1)

Sensory Nerve Conduction Study (SNCS)

Sensory Nerve Action Potential (SNAP)

Sensory nerve conduction velocity (SNCV)

Dorsal root ganglia (DRG)

References

1. D'Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. *Orphanet J Rare Dis.* 2011;6:71.
2. Hamilton G, Gillingwater TH. Spinal muscular atrophy: going beyond the motor neuron. *Trends in molecular medicine.* 2013;19:40–50.
3. Shababi M, Lorson CL, Rudnik-Schoneborn SS. Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease? *Journal of anatomy.* 2014;224:15–28.
4. Simone C, Ramirez R, Bucchia M, Rinchetti P, Rideout H, Papadimitriou D. Is Spinal Muscular Atrophy a disease of the motor neurons only: pathogenesis and therapeutic implications? *Cell Mol Life Sci.* 2016;73:1003–1020.
5. Imlach, W.L., Beck, E.S., Choi, B.J., Lotti, F., Pellizzoni, L., McCabe, B.D., 2012. SMN is required for sensory-motor circuit function in *Drosophila*. *Cell* 151, 427–439.
6. Lotti, F., Imlach, W.L., Saieva, L., Beck, E.S., Hao, L.T., Li, D.K., Jiao, W., Mentis, G.Z., Beattie, C.E., McCabe, B.D., Pellizzoni, L., 2012. An SMN-dependent U12 splicing event essential for motor circuit function. *Cell* 151, 440–454.
7. Mentis, G.Z., Blivis, D., Liu, W., Drobac, E., Crowder, M.E., Kong, L., Alvarez, F.J., Sumner, C.J., O'Donovan, M.J., 2011. Early functional impairment of sensory-motor connectivity in a mouse model of spinal muscular atrophy. *Neuron* 69, 453–467.
8. Jablonka S, Karle K, Sandner B, Andreassi C, von Au K, Sendtner M. Distinct and overlapping alterations in motor and sensory neurons in a mouse model of spinal muscular atrophy. *Hum Mol Genet* 2006;15:511–518.
9. Ling KK, Lin MY, Zingg B, Feng Z, Ko CP. Synaptic defects in the spinal and neuromuscular circuitry in a mouse model of spinal muscular atrophy. *PLoS One* 2010;5:e15457.

- Accepted Article
10. Wishart TM, Huang JP, Murray LM, Lamont DJ, Mutsaers CA, Ross J. SMN deficiency disrupts brain development in a mouse model of severe spinal muscular atrophy. *Hum Mol Genet.* 2010;19:4216-28.
 11. Martinez TL, Kong L, Wang X, Osborne MA, Crowder ME, Van Meerbeke JP. Survival motor neuron protein in motor neurons determines synaptic integrity in spinal muscular atrophy. *J Neurosci.* 2012;32:8703-8715.
 12. Carpenter S, Karpatis G, Rothman S. et al. Pathological involvement of primary sensory neurons in Werdnig-Hoffmann disease. *Acta Neuropathol (Berl).* 1978;42:91—97.
 13. Chien YY, Nonaka I. Peripheral nerve involvement in Werdnig-Hoffmann disease. *Brain and Development.* 1989;4:221-229.
 14. Omran H, Ketelsen UP, Heinen F, Sauer M, Rudnik-Schöneborn S, Wirth B et al. Axonal neuropathy and predominance of type II myofibers in infantile spinal muscular atrophy. *J Child Neurol.* 1998;13:327-331.
 15. Ravid S, Topper L, Eviatar L. Acute onset of infantile spinal muscular atrophy. *Pediatr Neurol.* 2001;24:371-372.
 16. Rudnik-Schöneborn S, Goebel HH, Schlote W, Molaian S, Omran H, Ketelsen U, et al. Classical infantile spinal muscular atrophy with SMN deficiency causes sensory neuronopathy. *Neurology.* 2003;60:983-987.
 17. Sultan HE, El-Emary WS. Sensory changes in pediatric patients with spinal muscular atrophy: an electrophysiologic study. *Egyptian Rheumatology and Rehabilitation.* 2016;43:1-6.
 18. Duman O, Uysal H, Skjei KL, et al. Sensorimotor polyneuropathy in patients with SMA type-1: electroneuromyographic findings. *Muscle Nerve.* 2013;48:117–121.


- Accepted Article
19. Korinthenberg R, Sauer M, Ketelsen U-P, Hanemann CO, Stoll G, Graf M, et al. Congenital axonal neuropathy caused by deletions in the spinal muscular atrophy region. *Ann Neurol* 1997;42:364–368.
20. Anagnostou, E., Miller, S.P., Guiot, M.-C., Karpati, G., Simard, L., Dilenge, M.-E., Shevell, M.I. Type I spinal muscular atrophy can mimic sensory-motor axonal neuropathy. *J. Child Neurol* 2005;20:147–150.
21. Munsat TL, Davies KS. International SMA consortium meeting (26 –28 June 92, Bonn, Germany). *Neuromuscul Disord.* 1992;2:423– 428.
22. Ryan CS, Conlee EM, Sharma R, Sorenson EJ, Boon AJ and Laughlin RS. Nerve conduction normal values for electrodiagnosis in pediatric patients. *Muscle Nerve.* 2019;60:155-160.
23. Shorrock H. K., van der Hoorn D., Boyd P. J., Llaverro Hurtado M., Lamont D. J., Wirth B., et al. UBA1/GARS-dependent pathways drive sensory-motor connectivity defects in spinal muscular atrophy. *Brain* 2018;141:2878–2894.
24. Fletcher E. V., Mentis G. Z. “Motor circuit dysfunction in spinal muscular atrophy,” in *Spinal Muscular Atrophy* eds Sumner C. J., Paushkin S., Ko C. P., editors. (London: Elsevier;) 2016;153–165.
25. Novartis (2019); <https://www.novartis.com/news/media-releases/novartis-announcesavxs-101-intrathecal-study-update>.

Figure.1 SNAP amplitudes and SNCV values by age. Linear trends for normal and SMA-1 patients are displayed with dotted lines.

Table.1 Median and IQ range of Sural and Medial nerve data.

		Sural Nerve		Median Nerve	
	Number	<i>Amplitude (μV)</i>	<i>SNCV (m/s)</i>	<i>Amplitude (μV)</i>	<i>SNCV (m/s)</i>
		<i>mean±SD</i>	<i>mean±SD</i>	<i>mean±SD</i>	<i>mean±SD</i>
		<i>Median (IQ range)</i>	<i>Median (IQ range)</i>	<i>Median (IQ range)</i>	<i>Median (IQ range)</i>
6-24 months					
SMA 1	9	16.9 (14.3-20.1)	48.7 (47.5-53.3)	45.1 (41.5-46.8)	46.7 (44.1-46.9)
Normative Data	23	15.0 (12.9-17.8)	46.4 (42.2-30.0)	29.7 (22.5-42.7)	47.1 (39.4-50.0)
p		0.133	0.409	0.034	0.742
3-6 years					
SMA 1	10	17.7 (15.0-23.8)	50.0 (49.6-51.4)	48.9 (44.5-56.9)	51.4 (49.8-54.8)
Normative Data	26	18.1 (14.8-23.8)	52.5 (46.7-59.3)	49.1 (31.7-61.9)	50.0 (44.8-54.1)
p		0.715	0.214	0.958	0.117
7-16 years					
SMA 1	9	3.9 (0-8.5)	44.4 (0-47.0)	17.0 (7.3-21.0)	63.8 (25.0-57.0)
Normative Data	44	22.6 (17.3-26.3)	52.4 (49.1-55.6)	43.8 (34.0-55.6)	51.1 (47.2-55.4)
p		<0.01	<0.01	<0.01	0.666

Abbreviations: SMA 1 (Spinal Muscular Atrophy type 1); SNCV (Sensory Nerve Conduction Velocity). Bold font indicates p<0.05



MUS_27389_Fig.1.jpg